Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Freegold Drills 1.43 g/t Au over 74.9 m at Golden Summit as 50,000 m 2026 Drill Program Accelerates Towards PFS
Thistle Resources Inc Commences Trading on the TSX Venture Exchange and Introduces the Middle River Gold Project
LaFleur Minerals Strengthens Leadership with Former Probe Gold and Probe Mines Executives to Accelerate Exploration Growth and Beacon Gold Mill Restart
